Evaluating Pregabalin and Crisugabalin for Treating Moderate to Severe Fibromyalgia in Adults

What this Trial Is About

Fibromyalgia FM is a long-lasting pain condition marked by widespread pain, tiredness, and emotional difficulties. It is linked to changes in the nervous system and chemical imbalances. Current treatments like pregabalin only help some patients and often cause side effects. Researchers are studying pregabalin and a newer drug called crisugabalin to see which might provide better relief and safety for people with FM. Participants will be randomly assigned to one of two groups one group will receive pregabalin starting at 150 mg daily with possible increases up to 450 mg daily based on how well it works and is tolerated. The other group will receive crisugabalin starting at 20 mg twice daily, with a maximum dose of 40 mg twice daily. The study will last about 12 weeks to assess these treatments. During the study, participants will regularly report their pain levels and complete questionnaires about their health, sleep, mood, and daily function. Researchers will monitor medication doses, use of additional pain relief, and any side effects throughout the 12 weeks. The main goal is to see how many patients experience pain relief at 12 weeks, with other measures taken at various points to understand the treatments effects and safety.

The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia